Panmure Gordon Reaffirms "Buy" Rating for Allergy Therapeutics plc

‘s stock had its “buy” rating restated by analysts at Panmure Gordon in a note issued to investors on Monday, Market Beat Ratings reports. They currently have a GBX 51 price target on the stock.